Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis

Inclusion Criteria: * Subject is ≥ 18 years of age. * Subject is diagnosed with non-infectious intermediate-, posterior-, or pan-uveitis. * Subject must have active disease at baseline as defined by the presence of at least 1 of the following parameters in at least one eye despite at least 2 weeks of prednisone ≥ 10 mg/day (or oral corticosteroid equivalent): * Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion * ≥ 1+ anterior chamber cells (Standardization of Uveitis Nomenclature \[SUN\] criteria) * ≥ 1+ vitreous haze (National Eye Institute \[NEI\]/SUN criteria) * Subject with documented prior adequate response to oral corticosteroids (equivalent of oral prednisone up to 1 mg/kg/day). * If subject is on prednisone \>=10 mg (or corticosteroid equivalent) at baseline, the dose has not been increased or decreased in the past 14 days. * No increase in the immune modulatory therapy in the past three months * Negative PPD test. * Positive PPD test on anti Tb medications. Exclusion Criteria: * Subject with isolated anterior uveitis. * Subject with confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to TB, cytomegalovirus, lyme disease, toxoplasmosis and herpes simplex virus (HSV). * Subject with serpiginous choroidopathy. * Subject with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial. * Subject with corneal or lens opacities that preclude the evaluation of the vitreous haze. * Subject with uncontrolled high intraocular pressure of ≥ 25 mmHg on maximal therapy. * Subject with intermediate uveitis and symptoms and/or MRI findings suggestive of a demyelinating disease such as multiple sclerosis. All subjects with intermediate uveitis must have had a prior brain MRI at time of or after diagnosis of intermediate uveitis. * Subject has received glucocorticosteroids implant (Retisert®), or Ozurdex within 6 months prior to baseline visit. * Subject has received intraocular or periocular corticosteroids or intravitreal methotrexate within 90 days prior to Baseline visit. * Subject with proliferative or severe non-proliferative diabetic retinopathy. * Subject with neovascular/wet age-related macular degeneration * Subject with abnormality of vitreo-retinal interface (i.e., vitreomacular traction, epiretinal membranes, etc.) with the potential for macular structural damage independent of the inflammatory process. * Subject with a systemic inflammatory disease and requires additional therapy with a systemic immunosuppressive agent at the time of study entry. * Subjects with history of active or latent Mycobacterium tuberculosis documented by Purified Protein Derivative (PPD) and chest X-ray and not anti tuberculosis (TB) treatment.